Levodopa Benserazid Beta

Levodopa and Benserazide, the active ingredients in Levodopa Benserazid Beta, are a dopamine precursor and a dopa‑decarboxylase inhibitor presented as an oral tablet for oral use. They are used to increase central dopamine levels and alleviate motor symptoms in patients with Parkinson's disease and related Parkinsonian syndromes.

GNH USA supplies Levodopa Benserazid Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets and providing reliable logistics for global distribution.

Levodopa/Benserazide is indicated for the management of Parkinsonian disorders, acting on the dopaminergic pathway to improve motor function.

- Parkinson's disease: reduces bradykinesia, rigidity and tremor, improving daily activities. - Parkinsonian syndrome: alleviates motor symptoms associated with secondary Parkinsonism. - Off‑period symptoms in Parkinson's disease: smooths fluctuations in motor control during dosing intervals.

Levodopa/Benserazide may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional emesis after dosing. - Orthostatic hypotension: dizziness upon standing. - Dizziness: transient light‑headedness. - Dyskinesia: involuntary movements with higher doses. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Severe hypotension: marked blood‑pressure drop requiring medical attention. - Neuroleptic malignant syndrome: life‑threatening reaction when combined with dopamine antagonists. - Cardiac arrhythmias: irregular heart rhythm in susceptible patients. - Hallucinations or psychosis: visual disturbances or delusional thoughts. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Respiratory depression: rare but critical breathing difficulty.

Levodopa/Benserazide requires careful clinical monitoring.

- Dose titration: start low and increase gradually to minimize dyskinesia. - Monitor for dyskinesia: adjust dose if involuntary movements appear. - Avoid high‑protein meals: protein can reduce levodopa absorption. - Caution in hepatic/renal impairment: dose may need adjustment. - Do not discontinue abruptly: taper under medical supervision. - Store below 25°C: keep in the original pack, protect from moisture.

Levodopa/Benserazide interacts with several medicines and substances.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine antagonists): may block therapeutic effect. - Pyridoxine (vitamin B6): enhances peripheral decarboxylation, reducing efficacy. - High‑protein meals: compete for transport, decreasing central availability. - Iron or antacids: may chelate levodopa, lowering absorption.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering. - Selective MAO‑B inhibitors: may increase dopaminergic activity. - SSRIs or SNRIs: potential for serotonin syndrome. - Other dopaminergic drugs (e.g., bromocriptine): may increase dyskinesia risk. - Diuretics: may affect fluid balance and blood pressure.